Heterocyclic Complexes of Ruthenium(III) Induce Apoptosis in Colorectal Carcinoma Cells

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2004 Oct 27

PMID 15503135

Citations 42

Authors

S Kapitza

M Pongratz

M A Jakupec

P Heffeter

W Berger

L Lackinger

B K Keppler

B Marian

Affiliations

Soon will be listed here.

Abstract

Purpose: The ruthenium complex salt indazolium trans-[tetrachlorobisindazole-ruthenate(III)] (KP1019) and the analogous sodium salt KP1339 are effective tumor-inhibiting drugs in experimental therapy of autochthonous colorectal carcinomas in rats. This paper examines the cell biological mechanisms underlying their antineoplastic effects.

Methods: Colorectal tumor cell lines were used to analyze uptake of the ruthenium(III) complexes into the cells and the mechanism as well as the efficacy of their cytotoxic effects.

Results: KP1019 and KP1339 are efficiently taken up into the cells: 100 microM ruthenium(III) complex in the growth medium led to the uptake of 120-160 ng ruthenium per 10(6) cells within 30 min. Uptake of KP418 was tenfold lower correlating with its lower cytotoxic efficiency. KP1019 and KP1339 induced apoptosis in SW480 and HT29 cells predominantly by the intrinsic mitochondrial pathway as indicated by loss of mitochondrial membrane potential. Correspondingly sensitivity of the cells paralleled expression of bcl(2) while it was only slightly affected by mutations in Ki-ras.

Conclusions: Our data demonstrate that trans-[tetrachlorobisindazole-ruthenate(III)] complex salts are promising candidate drugs in the second-line treatment of colorectal cancers resistant to other cytostatic drugs and has been introduced into phase I clinical trials.

Citing Articles

Die Wechselwirkung mit ribosomalen Proteinen begleitet die Stressinduktion des Wirkstoffkandidaten BOLD-100/KP1339 im endoplasmatischen Retikulum.

Neuditschko B, Legin A, Baier D, Schintlmeister A, Reipert S, Wagner M Angew Chem Weinheim Bergstr Ger. 2024; 133(10):5121-5126.

PMID: 38505777 PMC: 10947255. DOI: 10.1002/ange.202015962.

RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines.

Albanell-Fernandez M, Oltra S, Orts-Arroyo M, Ibarrola-Villava M, Carrasco F, Jimenez-Marti E Cancers (Basel). 2023; 15(1).

PMID: 36612065 PMC: 9817854. DOI: 10.3390/cancers15010069.

Molecular Design, Spectroscopic, DFT, Pharmacological, and Molecular Docking Studies of Novel Ruthenium(III)-Schiff Base Complex: An Inhibitor of Progression in HepG2 Cells.

Noureldeen A, Aziz S, Shouman S, Mohamed M, Attia Y, Ramadan R Int J Environ Res Public Health. 2022; 19(20).

PMID: 36294202 PMC: 9603487. DOI: 10.3390/ijerph192013624.

Metallo-Drugs in Cancer Therapy: Past, Present and Future.

Lucaciu R, Hangan A, Sevastre B, Oprean L Molecules. 2022; 27(19).

PMID: 36235023 PMC: 9572156. DOI: 10.3390/molecules27196485.

Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms.

Hildebrandt J, Hafner N, Kritsch D, Gorls H, Durst M, Runnebaum I Int J Mol Sci. 2022; 23(9).

PMID: 35563367 PMC: 9102668. DOI: 10.3390/ijms23094976.

References

Frasca D, Ciampa J, Emerson J, Umans R, Clarke M . Effects of hypoxia and transferrin on toxicity and DNA binding of ruthenium antitumor agents in hela cells. Met Based Drugs. 1996; 3(4):197-209. PMC: 2365025. DOI: 10.1155/MBD.1996.197. View

Galeano A, Berger M, Keppler B . Antitumor activity of some ruthenium derivatives in human colon cancer cell lines in vitro. Arzneimittelforschung. 1992; 42(6):821-4. View

Krajewska M, Moss S, Krajewski S, Song K, Holt P, Reed J . Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res. 1996; 56(10):2422-7. View

Cossarizza A, Kalashnikova G, Franceschi C . A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun. 1993; 197(1):40-5. DOI: 10.1006/bbrc.1993.2438. View

Lipponer K, Vogel E, Keppler B . Synthesis, Characterization and Solution Chemistry of trans-Indazoliumtetrachlorobis(Indazole)Ruthenate(III), a New Anticancer Ruthenium Complex. IR, UV, NMR, HPLC Investigations and Antitumor Activity. Crystal Structures of.... Met Based Drugs. 1996; 3(5):243-60. PMC: 2366238. DOI: 10.1155/MBD.1996.243. View

Peng K, Cluzeaud F, Bens M, Duong van Huyen J, Wioland M, Lacave R . Tissue and cell distribution of the multidrug resistance-associated protein (MRP) in mouse intestine and kidney. J Histochem Cytochem. 1999; 47(6):757-68. DOI: 10.1177/002215549904700605. View

Green D, Reed J . Mitochondria and apoptosis. Science. 1998; 281(5381):1309-12. DOI: 10.1126/science.281.5381.1309. View

Dong Z, Radinsky R, Fan D, Tsan R, Bucana C, Wilmanns C . Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J Natl Cancer Inst. 1994; 86(12):913-20. DOI: 10.1093/jnci/86.12.913. View

Tomonaga M, Oka M, Narasaki F, Fukuda M, Nakano R, Takatani H . The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers. Jpn J Cancer Res. 1996; 87(12):1263-70. PMC: 5921022. DOI: 10.1111/j.1349-7006.1996.tb03142.x. View

10.

Long B, Wang L, Lorico A, Wang R, Brattain M, CASAZZA A . Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res. 1991; 51(19):5275-83. View

11.

Macdonald J, Astrow A . Adjuvant therapy of colon cancer. Semin Oncol. 2001; 28(1):30-40. DOI: 10.1016/s0093-7754(01)90043-0. View

12.

Kratz F, Hartmann M, Keppler B, Messori L . The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. J Biol Chem. 1994; 269(4):2581-8. View

13.

Fearon E, Vogelstein B . A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759-67. DOI: 10.1016/0092-8674(90)90186-i. View

14.

Macdonald J . Adjuvant therapy of colon cancer. CA Cancer J Clin. 2001; 49(4):202-19. DOI: 10.3322/canjclin.49.4.202. View

15.

Berger M, Garzon F, Keppler B, Schmahl D . Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats. Anticancer Res. 1989; 9(3):761-5. View

16.

Fruhauf S, Zeller W . New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells. Cancer Res. 1991; 51(11):2943-8. View

17.

Violette S, Poulain L, Dussaulx E, Pepin D, Faussat A, Chambaz J . Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer. 2002; 98(4):498-504. DOI: 10.1002/ijc.10146. View

18.

Hinoshita E, Uchiumi T, Taguchi K, Kinukawa N, Tsuneyoshi M, Maehara Y . Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res. 2000; 6(6):2401-7. View

19.

Partik G, Sedivy R, Ellinger A, Bursch W, Marian B . Apoptosis in human colorectal tumours: ultrastructure and quantitative studies on tissue localization and association with bak expression. Virchows Arch. 1998; 432(5):415-26. DOI: 10.1007/s004280050185. View

20.

Ragnhammar P, Hafstrom L, Nygren P, Glimelius B . A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol. 2001; 40(2-3):282-308. DOI: 10.1080/02841860151116367. View